No products in the cart.
#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma
Click to read this study in the Journal of Clinical Oncology.
Tag: skin cancer
#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma
Click to read this study in The Lancet Oncology.
#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers
Click to read this study in the Journal of the American Academy of Dermatology.
#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers
Click to read this study in JAMA Dermatology.
#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas
Click to read this study in the Journal of the American Academy of Dermatology.
#VisualAbstract: Differences in Merkel cell carcinoma recurrence and survival rates stratified by cancer stage
Click to read this study in JAMA Dermatology.
#VisualAbstract: Cutaneous squamous cell carcinoma with satellitosis or in-transit metastasis shows similar survival to node-positive disease
Click to read this study in JAMA Dermatology.
#VisualAbstract: Time-of-infusion with immunotherapy may impact survival outcomes for patients with advanced melanoma
Click to read this study in Lancet Oncology.
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.